Ambrisentan - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Publication Date: Current

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers - Ambrisentan
Ambrisentan - indications: - Treatment of pulmonary arterial hypertension
Ambrisentan - innovator: Gilead (Letairis); Glaxosmithkline (Volibris)

Examples of information found in this online report include:

• Includes key patent publications for 44 countries - (see list below)
• Contains SPC protection for every EU state plus patent term extensions in other countries
• Data exclusivity calculated on a country by country basis
• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
• DMF & Paragraph IV filings
• Litigation alerts
• Marketing authorisation holders in selected territories
• Patent risk analysis via graphical display of data from patent filings
• Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. - (also available with 44 country coverage):

Pipeline Selector 44 Country Coverage:

Country - Region - Extensions
Australia - Asia-Pacific S70
Canada - Americas N/A
USA - Americas S156
Germany - Western Europe SPC
Great Britain - Western Europe SPCS
France - Western Europe NAT/SPC
Spain - Western Europe SPC
South Africa - Africa - N/A
China - Asia-Pacific - N/A
Japan - Asia-Pacific S67
New Zealand - Asia-Pacific - N/A
Bosnia & Herzegovina - Balkan - N/A
Bulgaria - Balkan - SPC
Croatia - Balkan - N/A
Romania - Balkan - SPC
Slovenia - Balkan - NAT/SPC
Estonia - Baltic - NAT/SPC
Lithuania - Baltic - NAT/SPC
Latvia - Baltic - NAT/SPC
Czech Republic - Central Europe - NAT/SPC
Hungary - Central Europe - SPC
Poland - Central Europe - SPC
Slovakia - Central Europe - NAT/SPC
Serbia & Montenegro - Central Europe - N/A
Cyprus - Mediterranean - NAT/SPC
Greece - Mediterranean - SPC
Israel - Mediterranean - NAT
Malta - Mediterranean - SPC
Turkey - Mediterranean - N/A
Denmark - Scandinavia - SPC
Finland - Scandinavia - SPC
Iceland - Scandinavia - SPC
Norway - Scandinavia - SPC
Sweden - Scandinavia - SPC
Brazil - South America - N/A
Mexico - South America - N/A
Austria - Western Europe SPC
Belgium - Western Europe - SPC
Switzerland - Western Europe - NAT/SPC
Ireland - Western Europe - SPC
Italy - Western Europe - NAT/SPC
Luxembourg - Western Europe SPC
The Netherlands - Western Europe - SPC
Portugal - Western Europe SPC

Other key information contained in the report:

• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**.
• News articles
• Litigation alerts
• Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.
• US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.
• Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.
• 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.

*Key Patent Indicator

The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report).

**General Drug Information

Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

***Patent Risk Analysis

The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.

Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Contents

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

• Includes key patent publications for 44 countries
• Contains SPC protection for every EU state plus patent term extensions in other countries
• Data exclusivity calculated on a country by country basis
• Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
• DMF & Paragraph IV filings
• Litigation alerts
• Marketing authorisation holders in selected territories
• Patent risk analysis via graphical display of data from patent filings
• Hyper-linking to crucial patent documents and national registries enabling data verification

Skip to top